La cadena de opciones muestra datos clave de las opciones de acciones de Medpace Hldgs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Medpace Hldgs..

Medpace Hldgs (NASDAQ:MEDP) Bolsa, Cadena de Opciones

Medpace Hldgs

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Medpace Holdings Inc

MedPeer Inc

Susquehanna analyst Joseph Stauff maintains Melco Resorts and Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLCO#NASDAQ">MLCO</a>) with a Positive and lowers the price target from $10 to $9.

News

Price Target

Analyst Ratings

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

Susquehanna Maintains Positive on Melco Resorts and Enter, Lowers Price Target to $9

PayPal Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) will be reporting fourth-quarter earnings on Tuesday. Wall Street expects $1.12 in EPS and $8.26 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=PYPL" target="_blank" rel="noreferrer noopener"> before market hours</a>.
The stock is up 42.22% over the past year, 1.55% YTD.
Let&#8217;s look at what the charts indicate for PayPal stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/trading-ideas/25/01/43175684/the-future-of-finance-3-fintech-stocks-set-to-take-wall-street-by-storm-in-2025">The Future of Finance: 3 Fintech Stocks Set to Take Wall Street by Storm in 2025</a>
<h2 class="wp-block-heading">PayPal Stock Strongly Bearish Ahead Of Q4 Earnings</h2>
PayPal stock is in a strongly bearish trend, with its share price of $87.64 trading below key exponential moving averages (EMAs) of five-day, 20-day and 50-day periods. This suggests continued selling pressure and an increased risk of further bearish movement. However, some technical indicators provide a more mixed outlook.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03104642/Screenshot-2025-02-03-at-9.16.30-PM.png" alt="" class="wp-image-762872" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03104642/Screenshot-2025-02-03-at-9.16.30-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03104642/Screenshot-2025-02-03-at-9.16.30-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
PayPal stock remains below its eight-day simple moving average (SMA) of $88.98, 20-day SMA of $88.47 and 50-day SMA of $87.93, signaling short-term weakness. The long-term trend, however, remains supportive, with PayPal stock well above its 200-day SMA of $73.72, reinforcing overall strength.
Momentum indicators show a neutral-to-bullish setup. The Moving Average Convergence Divergence (MACD) at 0.40 supports potential bullish movement, though the Relative Strength Index (RSI) at 48.00 suggests the stock is neither overbought nor oversold. 
PayPal stock investors should watch for a sustained move above key moving averages to confirm a shift toward bullish momentum or further downside if selling pressure persists.
<h2 class="wp-block-heading">PayPal Analysts See Limited Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/PYPL/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on PayPal stock stands at an Outperform currently with a price target of $90.30. Recent analyst ratings from Piper Sandler, Wells Fargo and Citigroup imply a 3.34% upside for PayPal stock with a $90 target.
PYPL Stock Price Action: PayPal stock was trading at $87.64 at the time of publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43437906/constellation-brands-most-exposed-name-as-trump-tariffs-go-live-analysts-advise-adjusting-prices">Constellation Brands &#8216;Most Exposed Name&#8217; As Trump Tariffs Go Live: Analysts Advise Adjusting Prices</a></li>
</ul>
Image: Shutterstock

Earnings

Fintech news covering the emerging Financial Technology services sector

Fintech

Technicals

Previews

Trading Ideas

PYPL

PayPal Stock In Danger Of Post-Earnings Dive? Q4 Preview Shows Risk

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) has abandoned plans for a $554.32 million (450 million pounds) vaccine manufacturing facility in the U.K. following disagreements with government officials over state support, marking a setback for Prime Minister Sir Keir Starmer's administration.
In August 2024, AstraZeneca reconsidered its planned investment in a new vaccine-manufacturing site, a departure from CEO&nbsp;Pascal Soriot's previous statement that the company was "absolutely ready to go."
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43273643/fda-approves-astrazeneca-daiichi-sankyos-enhertu-for-certain-type-of-breast-cancer-patients" rel="noreferrer noopener">FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients</a>
The U.K. Treasury, under the direction of&nbsp;Rachel Reeves, is reportedly considering decreasing government support for AstraZeneca by <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40526625/astrazeneca-threatens-to-move-vaccine-production-amid-reduced-state-support" rel="noreferrer noopener">over 20 million pounds</a>.
As a result, AstraZeneca said it might relocate the project from Speke in Merseyside, U.K., to France.
According to the Financial Times <a target="_blank" href="https://www.ft.com/content/c38f3342-7842-4c3a-876a-3a4403bed1a2" rel="noreferrer noopener">report</a> citing sources familiar with the matter, the pharmaceutical giant rejected a revised offer of 78 million pounds in financial aid after months of negotiations.
The U.K. government initially planned to provide around 90 million pounds in support under the previous Conservative administration, including 70 million pounds in grants and 20 million pounds for research and development.
However, after Labour took office last summer, officials reviewed AstraZeneca's proposed R&amp;D investment and concluded it was lower than expected.
As a result, the government reduced its support package to 40 pounds million. Although a later offer raised this figure to 78 million pounds, AstraZeneca ultimately turned it down.
The Financial Times <a target="_blank" href="https://www.ft.com/content/c38f3342-7842-4c3a-876a-3a4403bed1a2" rel="noreferrer noopener">report</a> adds that AstraZeneca also raised broader concerns about the UK's pharmaceutical environment during discussions about the Liverpool-based plant.
These included the NHS's rejection of its breast cancer drug Enhertu and the health service's approach to drug pricing, sources said.
One individual close to AstraZeneca described the industry's relationship with U.K. officials as "toxic," arguing that the country now has one of the least favorable commercial environments for pharmaceuticals in the Western world.
AstraZeneca recently announced a plan to invest C$820 million ($570 million)&nbsp;in Canada, creating&nbsp;more than 700 jobs <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43190131/astrazeneca-to-pump-570-million-into-canada-driving-expansion-job-growth" rel="noreferrer noopener">across all business areas</a>.
The&nbsp;investment&nbsp;will support the move to a larger, state-of-the-art office facility in the <a target="_blank" href="https://www.benzinga.com/topic/canada" rel="noreferrer noopener">greater Toronto area</a>.
Price Action: At last check on Monday, AZN stock was down 0.56% to $70.37.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43429620/triumph-group-reaches-3b-acquisition-deal-with-private-equity-investors" target="_blank" rel="noreferrer noopener">Triumph Group Agrees To Go Private In $3 Billion Acquisition Deal; Stock Jumps</a></li>
</ul>
Image by Robert Way via Shutterstock

Biotech

Government

Large Cap

Health Care

Media

General

AstraZeneca Blames 'Toxic' Climate As It Walks Away from Over $550 Million UK Vaccine Plant

Susquehanna analyst Charles Minervino maintains Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) with a Positive and raises the price target from $53 to $55.

Susquehanna Maintains Positive on Baker Hughes, Raises Price Target to $55

<a href="https://x.com/wsteaks/status/1886454081377435857" title="https://x.com/wsteaks/status/1886454081377435857">https://x.com/wsteaks/status/1886454081377435857</a>

Macro Economic Events

Politics

Economics

ABC News Reporter Will Steakin Posts On X "SoS Marco Rubio has been made acting administrator of USAID, multiple sources tell ABC News"

Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) shares are trading lower Monday after the<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43431003/cleveland-cliffs-provides-preliminary-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener"> company reported preliminary results</a>.
For the fourth quarter of 2024, Cleveland-Cliffs expects steel shipments of 3.8 million net tons, with revenues of around $4.30 billion <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">(vs. consensus of $4.49 billion)</a>.
Also, the company anticipates an adjusted EBITDA loss of about $85 million in the quarter.
For 2024, steel shipments are expected to reach 15.6 million net tons, with revenues around $19.2 billion (vs. street view of $19.37 billion) and adjusted EBITDA of around $775 million.
<a href="https://www.benzinga.com//node/41690362">Including Stelco</a>, the pro-forma adjusted EBITDA for 2024 is expected to be about $1.2 billion.
Cleveland-Cliffs attributed its weaker results, particularly in fourth-quarter, to subdued demand from the North American automotive sector.
Lourenco Goncalves, Cliffs&#8217; Chairman, President, and CEO, said, &#8221;So far into this new year, we have already seen improvements in our order book, both automotive and non-automotive, and are confident that the manufacturing-friendly items on President Trump&#8217;s agenda will have an outsized benefit on Cleveland-Cliffs.&#8221;
&#8221;This includes the recently announced tariffs on Mexico, Canada, and China and the expectation that there is more to come on steel specifically. Stelco has been a major contributor since day 1 and a substantial portion of our expected synergies are already in motion. Based on their experience in 2018, we expect Stelco will benefit from steel tariffs as well. We look forward to the success in 2025 that all of these developments will ultimately bring.&#8221;
&#8220;We applaud President Trump for taking decisive action on tariffs. Cleveland-Cliffs is a firm believer in the long-term positive impact that tariffs can play to make America a manufacturing superpower once again.&#8221;
Apart from this, Cleveland-Cliffs disclosed its intention to offer $750 million in Senior Guaranteed Notes due 2031, subject to market <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43431022/cleveland-cliffs-inc-announces-proposed-offering-of-750-million-of-senior-unsecured-guaranteed-not" rel="noreferrer noopener">conditions and other factors</a>.
The company plans to use the net proceeds for general corporate purposes, which includes the repayment of borrowings under its asset-based credit facility.
The company plans to release fourth-quarter and full-year 2024 earnings <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">results on February 24, 2025</a>.
Investors can gain exposure to the stock via SPDR S&amp;P Metals &amp; Mining ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XME#NYSE">XME</a>) and VanEck Steel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLX#NYSE">SLX</a>).
Price Action: CLF shares are down 2.64% at $9.97 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43230432/ancora-holdings-readies-proxy-fight-at-us-steel-amid-merger-chaos" target="_blank" rel="noreferrer noopener">Ancora Holdings Readies Proxy Fight At US Steel Amid Merger Chaos</a></li>
</ul>
Photo: Vladimir Mulder/Shutterstock.com.

Equities

Mid Cap

Guidance

Movers

Cleveland-Cliffs Predicts Q4 Revenue Miss & EBITDA Loss, CEO Applauds Trump's Tariffs For 2025 Boost

Cantor Fitzgerald analyst Troy Jensen reiterates Stratasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSYS#NASDAQ">SSYS</a>) with a Overweight and maintains $12 price target.

Reiteration

SSYS

Cantor Fitzgerald Reiterates Overweight on Stratasys, Maintains $12 Price Target

Senior White House Official Says Trump Administration Plans To Send Notification To Congress Soon Plans To Revamp USAID; Trump Has Entrusted Elon Musk To Oversee The Efficiency Of USAID

Stifel analyst Mark Astrachan maintains Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) with a Buy and lowers the price target from $113 to $105.

Stifel Maintains Buy on Intl Flavors & Fragrances, Lowers Price Target to $105

Stifel analyst Mark Astrachan maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Hold and lowers the price target from $115 to $105.

Stifel Maintains Hold on e.l.f. Beauty, Lowers Price Target to $105

Investors with significant funds have taken a bearish position in Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in BTDR usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 11 options transactions for Bitdeer Technologies. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 18% being bullish and 72% bearish. Of all the options we discovered, 10 are puts, valued at $647,878, and there was a single call, worth $36,540.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $17.5 for Bitdeer Technologies over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Bitdeer Technologies stands at 364.0, with a total volume reaching 17,200.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Bitdeer Technologies, situated within the strike price corridor from $15.0 to $17.5, throughout the last 30 days.
<h3>Bitdeer Technologies Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738601132_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTDR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$1.35</td>
<td>$1.15</td>
<td>$1.3</td>
<td>$17.50</td>
<td>$130.0K</td>
<td align="right">505</td>
<td>1.0K</td>
</tr>
<tr>
<td>BTDR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$1.3</td>
<td>$0.95</td>
<td>$1.25</td>
<td>$17.00</td>
<td>$125.0K</td>
<td align="right">59</td>
<td>1.0K</td>
</tr>
<tr>
<td>BTDR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$0.95</td>
<td>$0.8</td>
<td>$0.85</td>
<td>$16.00</td>
<td>$85.0K</td>
<td align="right">632</td>
<td>2.0K</td>
</tr>
<tr>
<td>BTDR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$0.75</td>
<td>$0.6</td>
<td>$0.75</td>
<td>$16.00</td>
<td>$74.4K</td>
<td align="right">632</td>
<td>1.0K</td>
</tr>
<tr>
<td>BTDR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$0.8</td>
<td>$0.75</td>
<td>$0.8</td>
<td>$16.00</td>
<td>$56.0K</td>
<td align="right">632</td>
<td>2.7K</td>
</tr>
</tbody>
</table>

<h3>About Bitdeer Technologies</h3>
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway.
Following our analysis of the options activities associated with Bitdeer Technologies, we pivot to a closer look at the company's own performance.
<h3>Current Position of Bitdeer Technologies</h3>
<ul>
<li>With a trading volume of 4,273,977, the price of BTDR is down by -6.86%, reaching $17.25.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 52 days from now.</li>
</ul>
<h3>What The Experts Say On Bitdeer Technologies</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $22.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Bitdeer Technologies with a target price of $22. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $22. 
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on Bitdeer Technologies, which currently sits at a price target of $22. 
&#x2A; Maintaining their stance, an analyst from Northland Capital Markets continues to hold a Outperform rating for Bitdeer Technologies, targeting a price of $24. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bitdeer Technologies options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

BTDR

Bitdeer Technologies's Options Frenzy: What You Need to Know

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 26 trades.
If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 38% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $1,549,640 and 17, calls, for a total amount of $974,753.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $140.0 for Moderna over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 982.53 with a total volume of 5,971.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $30.0 to $140.0 over the last 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738601127_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$6.5</td>
<td>$4.25</td>
<td>$5.2</td>
<td>$30.00</td>
<td>$780.0K</td>
<td>6.0K</td>
<td>1.5K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$1.6</td>
<td>$1.58</td>
<td>$1.6</td>
<td>$38.00</td>
<td>$329.2K</td>
<td>881</td>
<td>4</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.5</td>
<td>$10.25</td>
<td>$10.25</td>
<td>$40.00</td>
<td>$203.9K</td>
<td>1.6K</td>
<td>3</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.65</td>
<td>$45.00</td>
<td>$139.5K</td>
<td>2.1K</td>
<td>82</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$102.95</td>
<td>$102.25</td>
<td>$102.69</td>
<td>$140.00</td>
<td>$92.4K</td>
<td>59</td>
<td>1</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>With a volume of 4,167,881, the price of MRNA is down -5.18% at $37.38. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 11 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $66.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs has revised its rating downward to Neutral, adjusting the price target to $51. 
&#x2A; An analyst from UBS persists with their Buy rating on Moderna, maintaining a target price of $96. 
&#x2A; An analyst from Evercore ISI Group persists with their In-Line rating on Moderna, maintaining a target price of $50. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Moderna with a target price of $99. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Moderna, targeting a price of $38. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

MRNA

Moderna Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bearish stance on Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with INTC, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 33 uncommon options trades for Intel.
This isn't normal.
The overall sentiment of these big-money traders is split between 42% bullish and 51%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $184,784, and 27 are calls, for a total amount of $1,271,083.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $60.0 for Intel over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Intel stands at 7198.35, with a total volume reaching 45,279.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Intel, situated within the strike price corridor from $10.0 to $60.0, throughout the last 30 days.
<h3>Intel Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738601122_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.81</td>
<td>$2.77</td>
<td>$2.76</td>
<td>$18.00</td>
<td>$124.2K</td>
<td>1.6K</td>
<td>1.8K</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.55</td>
<td>$20.00</td>
<td>$88.7K</td>
<td>28.8K</td>
<td>474</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$0.55</td>
<td>$0.51</td>
<td>$0.51</td>
<td>$60.00</td>
<td>$76.8K</td>
<td>6.7K</td>
<td>1.8K</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.87</td>
<td>$2.68</td>
<td>$2.88</td>
<td>$18.00</td>
<td>$72.0K</td>
<td>1.6K</td>
<td>695</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$18.00</td>
<td>$70.0K</td>
<td>984</td>
<td>205</td>
</tr>
</tbody>
</table>

<h3>About Intel</h3>
Intel is a leading digital chipmaker, focused on the design and manufacturing of microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and was the prime proponent of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. Intel has also been expanding into new adjacencies, such as communications infrastructure, automotive, and the Internet of Things. Further, Intel expects to leverage its chip manufacturing capabilities into an outsourced foundry model where it constructs chips for others.
Having examined the options trading patterns of Intel, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Intel's Current Market Status</h3>
<ul>
<li>With a trading volume of 37,299,694, the price of INTC is up by 0.75%, reaching $19.57.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 80 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Intel, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

INTC

Check Out What Whales Are Doing With INTC

When you think of Warren Buffett's investments, you probably picture American icons like Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Dairy Queen, or even See's Candies—classic brands that embody his preference for simplicity and predictability. But in 2020, Buffett and Berkshire Hathaway made an uncharacteristic move. They turned their focus overseas, quietly pouring billions into Japan.&nbsp;
<a href="https://www.benzinga.com/personal-finance/24/12/42416245/charlie-munger-found-it-weird-how-life-was-pretty-brutal-and-short-but-now-things-are-600-better-and-yet-people-are-less-happy">Charlie Munger</a>, Buffett's longtime business partner and vice chairman of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>, BRK.B)), shared his thoughts on this unexpected investment. In October 2023, over dinner at his Los Angeles home, Munger sat down with the hosts of the Acquired podcast and reflected on a lifetime of wisdom, including this bold bet on Japan. He spoke with admiration for Buffett's ability to see opportunities where others didn't, calling the investment in Japan's five largest trading companies a "no-brainer."
Don't Miss:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
Berkshire's foray into Japan began in 2020, when the company purchased stakes in Itochu, Marubeni, Mitsubishi, Mitsui &amp; Co., and Sumitomo. Known as sogo shosha, these firms operate as general trading houses, deeply entrenched in Japan's economy with businesses spanning energy, mining, agriculture, and consumer goods. Buffett invested around $6 billion initially, taking advantage of Japan's historically low interest rates to fund the deal with yen-denominated bonds. These bonds carried yields of about 0.5%—practically free money—while the trading houses themselves offered steady dividend yields of approximately 5%.&nbsp;
Their diversified operations made them resemble mini versions of Berkshire itself, with reliable cash flow generated from their sprawling portfolios of assets.&nbsp;
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</a>
Munger <a href="https://www.benzinga.com/personal-finance/25/01/43166526/billionaire-warren-buffetts-first-wife-said-he-cared-about-the-win-not-the-money-its-all-mental-with-him-and-money-is-his-scorecard">emphasized that Buffett's patience</a>, combined with Berkshire's strong credit rating, was instrumental in making the investment successful. By financing the deal at historically low borrowing costs, Berkshire was able to gradually build its position while ensuring consistent returns.&nbsp;
Over the next few years, Berkshire gradually increased its stakes in the five trading houses. By late 2023, the positions had risen in value significantly, with Berkshire's investment growing to ¥2.9 trillion (about $20 billion), according to The Japan Times.
Munger's reflections on the investment weren't just about the numbers. For him, this was a textbook example of the <a href="https://www.benzinga.com/personal-finance/24/04/38275323/warren-buffett-warns-dont-watch-the-market-closely-urges-not-to-obsessively-check-stock-prices-i">principles he and Buffett had followed</a> throughout their careers. "If you're as smart as Warren Buffett, maybe two or three times a century, you have an idea like that," he said. Munger emphasized that the opportunity was so clear that it almost seemed too good to be true: "It was like having God just opening a chest and pouring money into it. Awfully easy money."
See Also: According to Juniper Research, the total value of B2B cross-border payments stored on the blockchain is projected to exceed $4.4 trillion — <a href="https://www.benzinga.com/money/web3-enabler-future-of-enterprise-transactions">Join the first company to bring blockchain payments to Salesforce early with just $100.</a>
The move also highlighted Buffett's rare ability to think globally while staying grounded in simple, fundamental principles. Historically, Berkshire's portfolio has leaned heavily toward American companies, reflecting its deep confidence in the U.S. economy. But this foray into Japan was proof that Buffett wasn't bound by geography—<a href="https://www.benzinga.com/news/25/01/42976301/charlie-munger-said-his-family-only-owns-3-stocks-damn-right-theyre-rich-because-diversification-is-for-know-nothing-investors">only by the opportunity itself</a>.&nbsp;
For Munger, who passed away just weeks after the interview at the age of 99, this investment was a final testament to the timeless principles he and Buffett spent their lives practicing: patience, discipline, and an uncanny ability to see opportunities others overlooked. Reflecting on Berkshire's success with the Japanese trading houses, Munger captured the simplicity of the strategy: "A huge flow of cash with no investment, no thought, no anything. How often do you do that?"
And with Buffett's trademark patience and precision, they did just that—turning a $6 billion initial investment into holdings worth nearly $20 billion in only a few short years.
Read Next:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Built on the trusted network of Fortune 500 companies, <a href="https://www.benzinga.com/money/web3-enabler-the-most-boring-blockchain-company-partners-with-salesforce">this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100.</a></li>
</ul>

Personal Finance

AAPL

Charlie Munger Praised Buffett's $20B 'No-Brainer' Investment In Japan: 'Like Having God Just Opening A Chest And Pouring Money Into It'

Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) has outperformed the market over the past 15 years by 10.56% on an annualized basis producing an average annual return of 22.7%. Currently, Super Micro Computer has a market capitalization of $15.97 billion. 
Buying $1000 In SMCI: If an investor had bought $1000 of SMCI stock 15 years ago, it would be worth $21,638.89 today based on a price of $27.27 for SMCI at the time of writing.
<h3>Super Micro Computer's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738601110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SMCI

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and raises the price target from $76 to $113.

PTCT

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $113

WIIM

SHOP

Shares of US-listed Canadian companies are trading lower following US tariffs.

Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) is set to report its fourth-quarter earnings after Tuesday's closing bell. Here's a look at what to <a href="https://www.benzinga.com/content/43419375/starbucks-ceo-led-turnaround-gains-traction-new-highs-likely">watch in the report.&nbsp;</a>
What To Watch: Investors will be watching Chipotle's average restaurant sales figures which came in at $3.08 million in the fourth quarter of 2023 and comparable store sales which grew 8.4% in the same quarter last year.&nbsp;
Chipotle outperformed competitors in terms of customer visits with year-over-year visit growth in each month of 2024, according<a href="https://www.placer.ai/blog/mcdonalds-chipotle-recapping-2024-visit-trends"> to data</a> from Placer.ai.&nbsp;
Stifel analysts released a preview note on Sunday and expect a "relatively in-line" quarter from the fast-casual chain. The analysts highlighted Chipotle's operational execution and product innovation, including its new Smoked Brisket offering which Stifel sees positively impacting overall margin performance.&nbsp;&nbsp;
Stifel analysts maintained a Buy rating and $70 price target on Chipotle shares.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/health-care/25/01/43372753/eggs-prices-soar-as-bird-flu-spreads-why-experts-expect-another-45-increase-in-2025">Eggs Prices Soar As Bird Flu Spreads: Why Experts Expect Another 45% Increase In 2025</a>
Chipotle's aggressive growth strategy will also be in focus with Stifel expecting between 110 and 120 new restaurants in the quarter based on webscraper data suggesting the company ended the year with between 3,725 and 3,735 stores.&nbsp;
Data from Placer.ai <a href="https://www.placer.ai/blog/mcdonalds-chipotle-recapping-2024-visit-trends">shows</a> that Chipotle's expansion strategy has proven successful with all but eight states in the U.S. showing growth in visits per location in 2024.&nbsp;
Multiple analysts updated coverage on Chipotle last week ahead of the company's Q4 release:&nbsp;
<ul>
<li>Citigroup analyst Jon Tower maintained Chipotle Mexican Grill with a Buy but lowered the price target from $70 to $69.</li>
<li>RBC Capital reiterated its Outperform rating and $75 price target.</li>
<li>Raymond James analyst Brian Vaccaro maintained Chipotle with an Outperform and lowered the price target from $72 to $69.</li>
<li>Bernstein analysts reiterated Chipotle with an Outperform and maintained a $70 price target on the stock.</li>
</ul>
According to estimates from<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"> Benzinga Pro</a>, analysts expect Chipotle to report earnings of 24 cents per share on quarterly revenue of $2.85 billion. The company has beat earnings expectations in each of the past five quarters but missed revenue estimates slightly last quarter.&nbsp;
Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Chipotle Mexican Grill shares are down 0.57% at $58.02 at the time of publication Monday. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43400701/ups-ceo-says-amazon-is-our-largest-but-not-our-most-profitable-customer">UPS CEO Says Amazon Is &#8216;Our Largest,&#8217; But &#8216;Not Our Most Profitable Customer&#8217;&nbsp;</a></li>
</ul>
Image: Shutterstock

Analyst Color

Restaurants

Chipotle Mexican Grill Q4 Earnings Preview: New Store Figures, Comparable Sales On Watch

Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) will be reporting its fourth-quarter earnings on Tuesday. Wall Street expects $2.06 in EPS and $4.15 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=SPOT" target="_blank" rel="noreferrer noopener"> before market hours</a>.
The stock is up 145.71% over the past year, 19.83% YTD.
Let&#8217;s look at what the charts indicate for Spotify stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/25/01/43237035/universal-music-and-spotify-partner-to-boost-artist-earnings-and-innovate-streaming-experience">Universal Music And Spotify Partner To Boost Artist Earnings And Innovate Streaming Experience</a>
<h2 class="wp-block-heading">SPOT Stock Strongly Bullish Ahead Of Q4 Earnings&#8230;</h2>
SPOT stock is in a strongly bullish trend, with its share price of $548.55 trading above key exponential moving averages (EMAs) of five-day, 20-day, and 50-day periods. However, selling pressure suggests a risk of potential bearish movement ahead. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03092307/Screenshot-2025-02-03-at-7.52.32-PM.png" alt="" class="wp-image-762757" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03092307/Screenshot-2025-02-03-at-7.52.32-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03092307/Screenshot-2025-02-03-at-7.52.32-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
SPOT stock remains above its eight-day simple moving average (SMA) of $523.47, 20-day SMA of $493.03 and 50-day SMA of $480.44, reinforcing short- and medium-term bullish momentum. Long-term strength is evident, with SPOT stock well above its 200-day SMA of $371.38, confirming an extended uptrend.
Momentum indicators signal both strength and caution. The Moving Average Convergence Divergence (MACD) at 20.53 supports continued bullish momentum, but the Relative Strength Index (RSI) at 76.7 suggests SPOT stock is overbought, potentially signaling a pullback.
Investors should watch for consolidation or a correction before considering new positions, as the stock nears levels where profit-taking could occur.
<h2 class="wp-block-heading">&#8230;Yet Spotify Analysts See Limited Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/SPOT/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Spotify stock stands at a Buy currently with a price target of $438.39. The latest analyst ratings from Keybanc, Macquarie and Cantor Fitzgerald imply a 3.28% upside for Spotify stock with a $560 price target.
SPOT Stock Price Action: Spotify stock was up 0.7% at $552.45 at last check on Monday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43286514/spotify-hits-milestone-10-billion-paid-to-music-industry-in-2024-60-billion-since-founding">Spotify Hits Milestone: $10 Billion Paid to Music Industry in 2024, $60 Billion Since Founding</a></li>
</ul>
Photo: Shutterstock

Entertainment

Signals

Tech

SPOT

Spotify Stock Rallies 145% In A Year: Will Q4 Earnings Keep The Music Playing?

Stifel analyst Mark Astrachan maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Hold and lowers the price target from $95 to $93.

Stifel Maintains Hold on Colgate-Palmolive, Lowers Price Target to $93

Miller-Howard Small Cap Dividend Q3 2024 Commentary

LVS Advisory Q4 2024 Letter

Medpace: What Earnings Growth Rate Could Justify The Valuation?

The Ithaka Group Q4 2024 Commentary

Vulcan Value Partners Q4 2024 Letter

AMID: Multi-Factor Mid-Cap ETF With Encouraging Results

MoneyShow's Best Investment Ideas For 2025: Part 6

Baird raised the firm's price target on Medpace (MEDP) to $362 from $354 and keeps a Neutral rating on the shares. The firm preiovewed its Q4 resul...

Medpace price target raised to $362 from $354 at Baird

Giverny Capital Asset Management Q4 2024 Letter

A Quest That Has Translated Into New Investments

ACIW

ADBE

ADMA

ALGN

ALLY

ALSN

AMID

AMKR

AMZN

ANET

ARMK

ASHTF

ASHTY

ASML

BBMC

BLDR

CACC

CHRD

CIEN

CMPGF

CMPGY

CNOB

CNOBP

CNSWF

COHR

CPRT

CRCQW

CTAS

ERFSF

FBIN

FELE

FERG

FICO

FIVE

FLQM

FTNT

GOOG

GOOGL

GRPM

GTBIF

HEINY

HINKF

HSTM

HWKN

ICHGF

IDCC

JHMM

KLIC

KNSL

LPLA

LULU

MEDP

MELI

MIDD

MOVAA

MSFT

NMRK

NVDA

OASPW

PDRDF

PGNY

PGPHF

PLTR

PRBZF

PRNDY

PTON

QRVO

QVMM

RKLIF

SCHW

SDTHF

SDXAY

SDXOF

SLVM

SMRT

TSLA

UAMY

UBER

VCCTF

VCTR

WLLAW

WLLBW

Press Releases

MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Medpace Holdings, Inc. and Encourages Investors to Contact the Firm

MEDP Investigation:  Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medpace Holdings, Inc. - MEDP

Legal

MEDP Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm

MEDPACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Medpace Holdings, Inc. on Behalf of Medpace Stockholders and Encourages Investors to Contact the Firm

MEDP Investigation Reminder:  Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm

MEDP Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm

Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 10, 2025

Comments

Medpace Hldgs

Medpace Hldgs (MEDP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL